PE20090183A1 - Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 - Google Patents

Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5

Info

Publication number
PE20090183A1
PE20090183A1 PE2008000546A PE2008000546A PE20090183A1 PE 20090183 A1 PE20090183 A1 PE 20090183A1 PE 2008000546 A PE2008000546 A PE 2008000546A PE 2008000546 A PE2008000546 A PE 2008000546A PE 20090183 A1 PE20090183 A1 PE 20090183A1
Authority
PE
Peru
Prior art keywords
dimethyl
diaza
oxa
undecan
ona
Prior art date
Application number
PE2008000546A
Other languages
English (en)
Inventor
Chris Richard Melville
David Mark Rotstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090183A1 publication Critical patent/PE20090183A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIPERIDINA DE FORMULA (I), DONDE R1 ES CICLOALQUILO C3-C6, (CICLOALQUILO C3-C6)-ALQUILO C1-C3HALOALQUILO C1-C3, ENTRE OTROS; R2 ES ALQUILO C1-C6; R3 ES H O ALQUILO C1-C3; R4 ES 4,6-DIMETIL-PIRIMIDIN-5-ILO, 4,6-DIMETIL-2-TRIFLUORMETIL-PIRIMIDIN-5-ILO, 2,4-DIMETIL-PIRIDIN-3-ILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-BUTIL-9-[1-(4,6-DIMETIL-PIRIMIDINA-5-CARBONIL)-4-METIL-PIPERIDIN-4-IL]-3-((1S,3S)-3-METOXI-CICLOHEXILMETIL)-1-OXA-3,9-DIAZA-ESPIRO[5.5]UNDECAN-2-ONA, 5-{4-[(S)-5-BUTIL-3-(4-HIDROXI-CICLOHEXILMETIL)-2-OXO-1-OXA-3,9-DIAZA-ESPIRO[5.5]UNDEC-9-IL]-4-MEYIL-PIPERIDINA-1-CARBONIL}-4,6-DIMETIL-PIRIDINA-2-CARBONITRILO, (S)-5-BUTIL-9-[1-(4,6-DIMETIL-PIRIMIDINA-5-CARBONIL)-4-METIL-PIPERIDIN-4-IL]-3-(HEXAHIDRO-FURO[2,3-b]FURAN-3-ILMETIL)-1-OXA-3,9-DIAZA-ESPIRO[5.5]UNDECAN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE QUIMIOQUINA CCR5 Y SON UTILES EN EL TRATAMIENTO DE INFECCIONES RETROVIRICAS DEL VIH-1, ARTRITIS REUMATOIDE, ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ENTRE OTRAS
PE2008000546A 2007-03-29 2008-03-26 Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 PE20090183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92069407P 2007-03-29 2007-03-29

Publications (1)

Publication Number Publication Date
PE20090183A1 true PE20090183A1 (es) 2009-03-12

Family

ID=39535486

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000546A PE20090183A1 (es) 2007-03-29 2008-03-26 Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5

Country Status (15)

Country Link
US (1) US7625891B2 (es)
EP (1) EP2142555A1 (es)
JP (1) JP2010522707A (es)
KR (1) KR20090127298A (es)
CN (1) CN101646679A (es)
AR (1) AR065854A1 (es)
AU (1) AU2008233930A1 (es)
BR (1) BRPI0809646A2 (es)
CA (1) CA2682639A1 (es)
CL (1) CL2008000863A1 (es)
IL (1) IL200661A0 (es)
MX (1) MX2009010503A (es)
PE (1) PE20090183A1 (es)
TW (1) TW200902020A (es)
WO (1) WO2008119663A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017664A1 (en) * 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
EP2229368A1 (en) 2007-12-11 2010-09-22 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
US8592409B2 (en) 2008-01-24 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5730021B2 (ja) * 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
US8138178B2 (en) * 2008-05-01 2012-03-20 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5696037B2 (ja) 2008-05-01 2015-04-08 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324018B1 (en) * 2008-07-25 2013-09-04 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
BRPI0919024A2 (pt) 2008-09-25 2019-09-24 Boehringer Ingelheim Int compostos que seletivamente modulam o receptor cb2
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
KR102061743B1 (ko) 2011-03-04 2020-01-03 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN108699013B (zh) * 2016-09-08 2022-05-06 嘉泉大学校校产学协力团 螺醌衍生物、其制备方法及含有其作为活性成分的用于预防或治疗神经疾患的药物组合物
CN109012748B (zh) * 2018-07-27 2021-03-16 安徽师范大学 吡啶取代吡咯基稀土金属催化剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (es) 1964-04-22
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
AU713235B2 (en) 1995-09-29 1999-11-25 Cor Therapeutics, Inc. Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
TR200402496T2 (tr) 1999-05-04 2005-01-24 Schering Corporation CCR5 antagonistleri olarak yararlı piperidin türevleri.
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
AU780888B2 (en) 1999-05-04 2005-04-21 Merck Sharp & Dohme Corp. Piperazine derivatives useful as CCR5 antagonists
TWI224597B (en) 1999-12-03 2004-12-01 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and a medicine containing the derivatives as an active ingredient
WO2001057044A1 (fr) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Derives de pyrido-oxazine
WO2002092604A1 (en) 2001-05-14 2002-11-21 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
DE60236206D1 (de) 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BRPI0507586A (pt) * 2004-02-10 2007-07-03 Hoffmann La Roche moduladores de receptor de quimiocina ccr5
EP1981911A2 (en) * 2006-01-30 2008-10-22 F.Hoffmann-La Roche Ag Synergistic compositions for treating hiv

Also Published As

Publication number Publication date
CL2008000863A1 (es) 2008-11-07
US20080249087A1 (en) 2008-10-09
TW200902020A (en) 2009-01-16
KR20090127298A (ko) 2009-12-10
CN101646679A (zh) 2010-02-10
JP2010522707A (ja) 2010-07-08
EP2142555A1 (en) 2010-01-13
US7625891B2 (en) 2009-12-01
CA2682639A1 (en) 2008-10-09
AR065854A1 (es) 2009-07-08
AU2008233930A1 (en) 2008-10-09
MX2009010503A (es) 2009-10-19
WO2008119663A1 (en) 2008-10-09
IL200661A0 (en) 2010-05-17
BRPI0809646A2 (pt) 2014-09-23

Similar Documents

Publication Publication Date Title
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
AR079231A1 (es) Derivados de imidazoquinolina
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20081776A1 (es) Moduladores 2-aminopirimidina del receptor histamina h4
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20090775A1 (es) Nuevos derivados de biarilo
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
UY29184A1 (es) Derivados de sulfonilbencimidazol
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20081897A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20091035A1 (es) Derivados de 2-aminopirimidina
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20081659A1 (es) Agonistas de gpcr
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119

Legal Events

Date Code Title Description
FD Application declared void or lapsed